Dr Roger Dansey | Senior Vice President and Therapeutic Area Head, Oncology Late-stage Development, Laboratories
Merck & Co.

Dr Roger Dansey, Senior Vice President and Therapeutic Area Head, Oncology Late-stage Development, Laboratories, Merck & Co.

Dr. Dansey joined MSD (known as Merck in the US and Canada) in January 2015 to lead the company’s late stage oncology development efforts including the recently approved PD-1 inhibitor, Keytruda®.   Prior to joining MSD, Dr. Dansey was Vice President, Oncology Clinical Research at Gilead Sciences where he led the development of the PI3 kinase delta inhibitor molecule, Zydelig®. Dansey initially joined the industry working at Amgen as a medical director on the Neulasta® program. He then moved into clinical roles of increasing responsibility in Amgen’s oncology and hematology therapeutic area.  Dr. Dansey led the development of Xgeva® and Prolia®, for the prevention of skeletal-related events in cancer patients with metastatic disease and the prevention of bone loss resulting from hormonal manipulation in patients with early-stage breast cancer or non-metastatic prostate cancer.
Dr. Dansey received his Medical Degrees from the University of Witwatersrand, Johannesburg South Africa.  Prior to joining industry, he held the position of Associate Professor of Medicine and Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University in Detroit, Michigan.


Agenda Day 2 @ 2:45

Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy

  • The past, present and future of anti-PD-1 therapies
  • Where are we currently with Keytruda monotherapy and biomarkers
  • Updates on our combination strategy and trials with Keytruda and other novel agents

back to speakers